fda update on semaglutide FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know The FDA's Decision to Ban

Last reviewed: June 27, 2026 Last updated: June 27, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

This tapering approach allows the body to gradually readjust to unmedicated appetite levels, reducing the rebound effect that many people experience with abrupt discontinuation

Here is what the key trials showed

If you're looking for a reliable source for high-quality compounded semaglutide, Ivy Rx provides expertly formulated options to help you stay on track